ID28699A - Turunan-turunan asam oksiiminoalkanoat - Google Patents
Turunan-turunan asam oksiiminoalkanoatInfo
- Publication number
- ID28699A ID28699A IDW20002324A ID20002324A ID28699A ID 28699 A ID28699 A ID 28699A ID W20002324 A IDW20002324 A ID W20002324A ID 20002324 A ID20002324 A ID 20002324A ID 28699 A ID28699 A ID 28699A
- Authority
- ID
- Indonesia
- Prior art keywords
- oxysiiminalaloic
- drivings
- acid
- oxysiiminalaloic acid
- acid drivings
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12792198 | 1998-05-11 | ||
JP12792298 | 1998-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ID28699A true ID28699A (id) | 2001-06-28 |
Family
ID=26463748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDW20002324A ID28699A (id) | 1998-05-11 | 1999-05-10 | Turunan-turunan asam oksiiminoalkanoat |
Country Status (27)
Country | Link |
---|---|
US (3) | US6251926B1 (id) |
EP (2) | EP1077957B1 (id) |
JP (1) | JP2000198772A (id) |
KR (1) | KR100388120B1 (id) |
CN (1) | CN1148361C (id) |
AR (1) | AR029876A1 (id) |
AT (1) | ATE272625T1 (id) |
AU (1) | AU766831B2 (id) |
BR (1) | BR9910371A (id) |
CA (1) | CA2331879A1 (id) |
CO (1) | CO5040066A1 (id) |
DE (1) | DE69919156T2 (id) |
ES (1) | ES2226377T3 (id) |
HK (1) | HK1034972A1 (id) |
HU (1) | HUP0103714A3 (id) |
ID (1) | ID28699A (id) |
IL (1) | IL139470A0 (id) |
LV (1) | LV12606B (id) |
MY (1) | MY123337A (id) |
NO (1) | NO317426B1 (id) |
NZ (1) | NZ508066A (id) |
PE (1) | PE20000625A1 (id) |
PL (1) | PL344002A1 (id) |
PT (1) | PT1077957E (id) |
RU (1) | RU2213738C2 (id) |
SK (1) | SK16412000A3 (id) |
WO (1) | WO1999058510A1 (id) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY123337A (en) * | 1998-05-11 | 2006-05-31 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives. |
TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
ES2204684T3 (es) * | 1999-08-27 | 2004-05-01 | Eli Lilly And Company | Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar. |
DE19948126A1 (de) * | 1999-10-06 | 2001-04-12 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock |
KR20020051925A (ko) * | 1999-10-29 | 2002-06-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 옥시이미노알카노산 유도체의 제조 방법 |
TW558554B (en) | 1999-10-29 | 2003-10-21 | Takeda Chemical Industries Ltd | Crystals of oxyiminoalkanoic acid derivative |
CN1423566A (zh) * | 1999-11-10 | 2003-06-11 | 武田药品工业株式会社 | 体重增加抑制剂 |
CA2390928A1 (en) * | 1999-11-10 | 2001-05-17 | Takeda Chemical Industries, Ltd. | Alkoxyiminoalkanoic acid derivatives |
PT1228067E (pt) | 1999-11-10 | 2004-11-30 | Takeda Chemical Industries Ltd | Compostos heterociclicos de cinco membros com actividade hipoglicemica e hipolipidemica |
WO2001072695A1 (fr) * | 2000-03-28 | 2001-10-04 | Takeda Chemical Industries, Ltd. | Inhibiteurs de la neovascularisation |
EP1310494B1 (en) * | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
CA2433573A1 (en) * | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
WO2002076959A1 (fr) * | 2001-03-23 | 2002-10-03 | Takeda Chemical Industries, Ltd. | Derive heterocyclique a cinq membres d'acide alcanoique |
US20040077689A1 (en) * | 2001-04-25 | 2004-04-22 | Yasuo Sugiyama | Abc expression promoters |
ATE352312T1 (de) * | 2001-12-29 | 2007-02-15 | Novo Nordisk As | Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors |
TWI343915B (en) * | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
WO2004037168A2 (en) * | 2002-10-18 | 2004-05-06 | Amylin Pharmaceuticals, Inc. | Treatment of pancreatitis with amylin |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
WO2004053103A2 (en) * | 2002-12-11 | 2004-06-24 | University Of Massachusetts | METHOD OF INTRODUCING siRNA INTO ADIPOCYTES |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
CN100438911C (zh) * | 2002-12-27 | 2008-12-03 | 武田药品工业株式会社 | 体重增加抑制剂 |
WO2005027967A1 (ja) * | 2003-09-17 | 2005-03-31 | Kaname Kawasugi | 医薬組成物 |
EP1718604A4 (en) * | 2004-02-24 | 2008-02-13 | Irm Llc | COMPOUNDS AND COMPOSITIONS OF IMMUNOSUPPRESSANTS |
CA2560928A1 (en) * | 2004-03-29 | 2005-10-06 | Sankyo Company Limited | Therapeutic agent for diabetes containing insulin resistance improving agent |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
WO2006030753A1 (ja) * | 2004-09-13 | 2006-03-23 | Santen Pharmaceutical Co., Ltd. | 角結膜障害治療剤 |
US7556933B2 (en) * | 2004-10-01 | 2009-07-07 | Luminultra Technologies Ltd. | Reagent system and process for adenosine triphosphate monitoring |
EP2308839B1 (en) | 2005-04-20 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
EP1887000A4 (en) | 2005-05-27 | 2011-09-07 | Shionogi & Co | ARYLACETATE DERIVATIVES WITH ISOXAZO EASY |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
US7491414B2 (en) * | 2005-10-12 | 2009-02-17 | Gaia Herbs, Inc. | Anti-inflammatory substances extracted from Echinacea |
WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素5員複素環化合物 |
JPWO2009128481A1 (ja) | 2008-04-16 | 2011-08-04 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
WO2010011302A1 (en) * | 2008-07-22 | 2010-01-28 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2010016552A1 (ja) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 過敏性腸症候群治療薬 |
EP2374007A2 (en) | 2008-12-04 | 2011-10-12 | IKFE GmbH | Biomarkers for atherosclerosis |
AU2009325962A1 (en) | 2008-12-11 | 2011-07-28 | Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh | Biomarkers for insulin sensitizer drug response |
EP2382467A1 (en) | 2008-12-30 | 2011-11-02 | IKFE GmbH | Biomarkers for adipose tissue activity |
US20100210541A1 (en) | 2009-01-07 | 2010-08-19 | Andreas Pfuetzner | Biomarkers for Appetite Regulation |
CN102875548A (zh) * | 2011-07-14 | 2013-01-16 | 中国科学院大连化学物理研究所 | 一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法 |
US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
JP6299591B2 (ja) | 2012-07-03 | 2018-03-28 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
PT3053916T (pt) | 2013-09-30 | 2019-03-26 | Ono Pharmaceutical Co | Composto com atividade agonista do recetor da somatostatina e utiliza ao farmaceutica do mesmo |
US20160083380A1 (en) * | 2013-12-16 | 2016-03-24 | Cadila Healthcare Limited | Oximino derivatives for the treatment of dyslipidemia |
US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
FR3042903B1 (fr) * | 2015-10-21 | 2017-12-08 | Commissariat Energie Atomique | Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
SG11201907240XA (en) | 2017-02-08 | 2019-09-27 | Ono Pharmaceutical Co | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
US11109683B2 (en) | 2019-02-21 | 2021-09-07 | Steelcase Inc. | Body support assembly and method for the use and assembly thereof |
US11357329B2 (en) | 2019-12-13 | 2022-06-14 | Steelcase Inc. | Body support assembly and methods for the use and assembly thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU177578B (en) | 1976-08-27 | 1981-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives |
JPS5849382A (ja) | 1981-09-18 | 1983-03-23 | Kyowa Hakko Kogyo Co Ltd | β−ラクタム化合物 |
JPS59167576A (ja) | 1983-03-15 | 1984-09-21 | Kyowa Hakko Kogyo Co Ltd | β−ラクタム化合物 |
JPS6277391A (ja) | 1984-12-21 | 1987-04-09 | Mochida Pharmaceut Co Ltd | セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤 |
JPS62158290A (ja) * | 1985-12-28 | 1987-07-14 | Banyu Pharmaceut Co Ltd | 新規セフアロスポリン誘導体 |
US4698338A (en) | 1986-02-19 | 1987-10-06 | Eli Lilly And Company | 7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins |
US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
JPH0277391A (ja) | 1988-09-14 | 1990-03-16 | Suzuki Motor Co Ltd | 水ジェット推進船のビルジ水排水装置 |
ATE169616T1 (de) | 1988-11-21 | 1998-08-15 | Zeneca Ltd | Zwischenverbindungen zur herstellung von fungiziden |
EP0400805A1 (en) | 1989-04-25 | 1990-12-05 | Toshiyasu Ishimaru | Cephalosporin compounds and their use |
JPH03115272A (ja) * | 1989-10-19 | 1991-05-16 | Banyu Pharmaceut Co Ltd | マンデル酸誘導体およびその製法 |
IE912046A1 (en) * | 1990-06-18 | 1991-12-18 | Fujisawa Pharmaceutical Co | New polypeptide compound and a process for preparation¹thereof |
ES2110421T5 (es) * | 1990-06-27 | 2004-12-01 | Basf Aktiengesellschaft | O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos. |
JPH04112890A (ja) * | 1990-09-04 | 1992-04-14 | Ajinomoto Co Inc | 新規チアゾール誘導体及び該誘導体を含有する抗菌剤 |
EP0486011A3 (en) * | 1990-11-16 | 1992-07-15 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition against pneumocystis carinii |
CA2100918C (en) * | 1992-07-21 | 1997-01-21 | Nobuyuki Hamanaka | Oxime derivative |
US5512581A (en) | 1994-07-18 | 1996-04-30 | Abbott Laboratories | Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis |
CA2159938A1 (en) | 1994-10-07 | 1996-04-08 | Hiroaki Yanagisawa | Oxime derivatives, their preparation and their therapeutic use |
CH689228A5 (de) | 1994-10-07 | 1998-12-31 | Novartis Ag | Oximether, sowie diese enthaltende Pflanzenschutzmittel. |
US5902726A (en) | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
US6022897A (en) | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
WO1996038427A1 (fr) * | 1995-06-02 | 1996-12-05 | Sankyo Company, Limited | Derives d'oxyimino aromatiques |
US5939442A (en) | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
FR2737893B1 (fr) * | 1995-08-16 | 1997-09-12 | Roussel Uclaf | Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
JPH09323929A (ja) | 1996-04-02 | 1997-12-16 | Sankyo Co Ltd | オキシム誘導体を含有する医薬 |
CN1104413C (zh) | 1996-04-04 | 2003-04-02 | 三共株式会社 | 苯基烷基羧酸衍生物 |
WO1998005331A2 (en) | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
EP1023907B1 (en) | 1997-07-24 | 2009-01-21 | Astellas Pharma Inc. | Medicinal compositions with cholesterol-lowering effect |
JPH11193272A (ja) | 1997-10-01 | 1999-07-21 | Sankyo Co Ltd | フェニルアルキルカルボン酸誘導体を含有する医薬 |
MY123337A (en) * | 1998-05-11 | 2006-05-31 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives. |
-
1999
- 1999-05-10 MY MYPI99001832A patent/MY123337A/en unknown
- 1999-05-10 AR ARP990102190A patent/AR029876A1/es unknown
- 1999-05-10 KR KR10-2000-7000081A patent/KR100388120B1/ko not_active IP Right Cessation
- 1999-05-10 HU HU0103714A patent/HUP0103714A3/hu unknown
- 1999-05-10 PT PT99918355T patent/PT1077957E/pt unknown
- 1999-05-10 IL IL13947099A patent/IL139470A0/xx unknown
- 1999-05-10 EP EP99918355A patent/EP1077957B1/en not_active Expired - Lifetime
- 1999-05-10 NZ NZ508066A patent/NZ508066A/xx unknown
- 1999-05-10 DE DE69919156T patent/DE69919156T2/de not_active Expired - Lifetime
- 1999-05-10 US US09/423,854 patent/US6251926B1/en not_active Expired - Fee Related
- 1999-05-10 AU AU36297/99A patent/AU766831B2/en not_active Ceased
- 1999-05-10 ES ES99918355T patent/ES2226377T3/es not_active Expired - Lifetime
- 1999-05-10 CA CA002331879A patent/CA2331879A1/en not_active Abandoned
- 1999-05-10 CN CNB998060070A patent/CN1148361C/zh not_active Expired - Fee Related
- 1999-05-10 SK SK1641-2000A patent/SK16412000A3/sk unknown
- 1999-05-10 ID IDW20002324A patent/ID28699A/id unknown
- 1999-05-10 EP EP04075569A patent/EP1428531A1/en not_active Withdrawn
- 1999-05-10 RU RU2000131183/04A patent/RU2213738C2/ru not_active IP Right Cessation
- 1999-05-10 WO PCT/JP1999/002407 patent/WO1999058510A1/en not_active Application Discontinuation
- 1999-05-10 AT AT99918355T patent/ATE272625T1/de not_active IP Right Cessation
- 1999-05-10 BR BR9910371-0A patent/BR9910371A/pt not_active IP Right Cessation
- 1999-05-10 PL PL99344002A patent/PL344002A1/xx not_active Application Discontinuation
- 1999-05-11 CO CO99029123A patent/CO5040066A1/es unknown
- 1999-05-11 PE PE1999000393A patent/PE20000625A1/es not_active Application Discontinuation
- 1999-12-28 JP JP11373202A patent/JP2000198772A/ja active Pending
-
2000
- 2000-11-01 LV LVP-00-148A patent/LV12606B/en unknown
- 2000-11-02 NO NO20005531A patent/NO317426B1/no unknown
- 2000-11-16 US US09/714,699 patent/US6495581B1/en not_active Expired - Fee Related
-
2001
- 2001-08-15 HK HK01105750A patent/HK1034972A1/xx not_active IP Right Cessation
-
2002
- 2002-12-27 US US10/331,056 patent/US6924300B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID28699A (id) | Turunan-turunan asam oksiiminoalkanoat | |
ID22799A (id) | Turunan-turunan asam arilsulfonilamino hidroksamat | |
ID22809A (id) | Turunan-turunan asam arilsulfonil hidroksamat | |
ID26978A (id) | Turunan-turunan asam aminometilkarboksilat | |
ID18063A (id) | Turunan-turunan asam arilsufonilamino hidroksamat | |
ID28833A (id) | Turunan asam 3-aril-2-hidroksipropionat | |
ID26222A (id) | Hidroksamida asam(4-arilsulfonilamino)-tetrahidropiran-4-karboksilat | |
ID20807A (id) | Asam sulfonilaminokarboksilat | |
ID20809A (id) | Asam diaminokarboksilat tersubstitusi | |
ID22095A (id) | Asam aril-akrilat ester | |
ID23668A (id) | Turunan asam ariloksiarilsulfonilamino hidroksamat | |
ATE269861T1 (de) | Substituierte indolalkansäure | |
ID24376A (id) | Turunan-turunan asam amidokarboksilat | |
ID24626A (id) | Turunan-turunan asam hidroksamat sebagai penghambat metaloprotease matriks (mmp) | |
ID23502A (id) | Pembuatan asam tereftalat | |
ID27390A (id) | Pembuatan asam akrilat | |
ID28164A (id) | Turunan iii asam 3-aril-2-hidroksipropionat baru | |
ID22863A (id) | Metoda untuk memproduksi bahan asam nukleat | |
NO993443L (no) | Kabinstruktur | |
ID26379A (id) | Katalis asam padat | |
ID28810A (id) | Senyawa-senyawa amida-omega asam n-arilsulfonilamino | |
ID17416A (id) | Pembuatan asam akrilat | |
NO991561D0 (no) | 3-alkoksyisoksazol-4-yl-substituerte 2-aminokarboksylsyreforbindelser | |
ID17052A (id) | Turunan-turunan asam asetat terapeutik | |
ID25990A (id) | Susunan dna |